AMAG has launched Feraheme (ferumoxytol) injection in the US. Feraheme is an intravenous iron replacement therapy, for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
Feraheme was approved by the FDA on June 30, 2009. The company will be marketing and selling Feraheme in the US through its commercial organization.
Feraheme is contraindicated in patients with evidence of iron overload, known hypersensitivity to Feraheme or any of its components, and patients with anemia not caused by iron deficiency, said the company.
AMAG is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound. It is intended to treat iron deficiency anemia and novel imaging agents, to aid in the diagnosis of cancer and cardiovascular disease.